Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company focused on genetic treatments for neurological diseases, reported its financial results for the second quarter of 2025. The company recorded a net loss of $33.4 million, a significant increase from the $10.1 million loss reported in the same period of 2024. This increase in net loss was attributed to a reduction in collaboration revenue. General and administrative expenses saw a slight rise to $10.5 million from $10.2 million in the previous year, primarily due to higher employee-related costs. As of June 30, 2025, Voyager's cash, cash equivalents, and marketable securities were reported at $262 million. The company has extended its cash runway into 2028, which is expected to support multiple meaningful clinical data read-outs. Voyager has also expanded its pipeline by adding the APOE program, marking its fourth asset in the Alzheimer's disease franchise. The company has 11 partnered programs with the potential to earn up to $2.6 billion in development-stage milestone payments, including up to $35 million from GBA and FA programs entering the clinic.